Comparison of clinical features in 165 adult Japanese patients with anti-aminoacyl-tRNA synthetase antibodies.^*

*Unless noted otherwise, values are percentages of patients. NS: not significant; CK: creatine kinase; LDH: lactate dehydrogenase. One patient with DM who had antibodies reactive to both PL-7 and PL-12 was excluded from the analysis. Significant differences (overall P<0.05) were further analyzed by pairwise comparisons. aP<0.05 between anti-PL-7 and anti-PL-12; P<0.01 between anti-Jo-1 and anti-PL-12, and between anti-KS and anti-Jo-1 or anti-PL-7; bP<0.05 between anti-Jo-1 and anti-PL-7 or anti-PL-12, and between anti-EJ and anti-PL-7; P<0.01 between anti-EJ and anti-PL-12. cP<0.05 between anti-EJ and anti-PL-12; P<0.01 between anti-Jo-1 and anti-PL-12, anti-KS or anti-OJ, between anti-EJ and anti-KS, and between anti-PL-7 and anti-PL-12, anti-KS or anti-OJ. dP<0.05 between anti-Jo-1 and anti-PL-7, anti-KS or anti-OJ; P<0.01 between anti-Jo-1 and anti-EJ or anti-PL-12. eP<0.05 between anti-Jo-1 and anti-EJ; P<0.01 between anti-PL-7 and anti-Jo-1 or anti-KS. fP<0.05 between anti-KS and anti-EJ or anti-PL-12; P<0.01 between anti-PL-7 and anti-KS. gP<0.05 between anti-Jo-1 and anti-PL-12 or anti-KS; P<0.01 between anti-Jo-1 and anti-EJ. hP<0.05 between anti-EJ and anti-PL-12 or anti-KS; P<0.01 between anti-Jo-1 and anti-PL-12 or anti-KS, and between anti-PL-7 and anti-PL-12 or anti-KS. iP<0.05 between anti-PL-7 and anti-PL-12; P<0.01 between anti-Jo-1 and anti-PL-12, and between anti-KS and anti-Jo-1, anti-EJ or anti-PL-7.*除非另有说明，所有数值均以患者百分比表示。NS：无统计学意义（not significant）；CK：肌酸激酶（creatine kinase）；LDH：乳酸脱氢酶（lactate dehydrogenase）。本研究排除1例同时存在可与PL-7和PL-12发生交叉反应的抗体的DM（皮肌炎，Dermatomyositis）患者。总体P<0.05的显著性差异进一步通过两两比较进行分析： a：抗PL-7抗体（anti-PL-7）与抗PL-12抗体（anti-PL-12）组间比较P<0.05；抗Jo-1抗体（anti-Jo-1）与抗PL-12抗体、抗KS抗体（anti-KS）与抗Jo-1抗体（anti-Jo-1）或抗PL-7抗体（anti-PL-7）组间比较P<0.01； b：抗Jo-1抗体（anti-Jo-1）与抗PL-7抗体（anti-PL-7）或抗PL-12抗体（anti-PL-12）、抗EJ抗体（anti-EJ）与抗PL-7抗体（anti-PL-7）组间比较P<0.05；抗EJ抗体（anti-EJ）与抗PL-12抗体（anti-PL-12）组间比较P<0.01； c：抗EJ抗体（anti-EJ）与抗PL-12抗体（anti-PL-12）组间比较P<0.05；抗Jo-1抗体（anti-Jo-1）与抗PL-12抗体（anti-PL-12）、抗KS抗体（anti-KS）或抗OJ抗体（anti-OJ）、抗EJ抗体（anti-EJ）与抗KS抗体（anti-KS）、抗PL-7抗体（anti-PL-7）与抗PL-12抗体（anti-PL-12）、抗KS抗体（anti-KS）或抗OJ抗体（anti-OJ）组间比较P<0.01； d：抗Jo-1抗体（anti-Jo-1）与抗PL-7抗体（anti-PL-7）、抗KS抗体（anti-KS）或抗OJ抗体（anti-OJ）组间比较P<0.05；抗Jo-1抗体（anti-Jo-1）与抗EJ抗体（anti-EJ）或抗PL-12抗体（anti-PL-12）组间比较P<0.01； e：抗Jo-1抗体（anti-Jo-1）与抗EJ抗体（anti-EJ）组间比较P<0.05；抗PL-7抗体（anti-PL-7）与抗Jo-1抗体（anti-Jo-1）或抗KS抗体（anti-KS）组间比较P<0.01； f：抗KS抗体（anti-KS）与抗EJ抗体（anti-EJ）或抗PL-12抗体（anti-PL-12）组间比较P<0.05；抗PL-7抗体（anti-PL-7）与抗KS抗体（anti-KS）组间比较P<0.01； g：抗Jo-1抗体（anti-Jo-1）与抗PL-12抗体（anti-PL-12）或抗KS抗体（anti-KS）组间比较P<0.05；抗Jo-1抗体（anti-Jo-1）与抗EJ抗体（anti-EJ）组间比较P<0.01； h：抗EJ抗体（anti-EJ）与抗PL-12抗体（anti-PL-12）或抗KS抗体（anti-KS）组间比较P<0.05；抗Jo-1抗体（anti-Jo-1）与抗PL-12抗体（anti-PL-12）或抗KS抗体（anti-KS）、抗PL-7抗体（anti-PL-7）与抗PL-12抗体（anti-PL-12）或抗KS抗体（anti-KS）组间比较P<0.01； i：抗PL-7抗体（anti-PL-7）与抗PL-12抗体（anti-PL-12）组间比较P<0.05；抗Jo-1抗体（anti-Jo-1）与抗PL-12抗体（anti-PL-12）、抗KS抗体（anti-KS）与抗Jo-1抗体（anti-Jo-1）、抗EJ抗体（anti-EJ）或抗PL-7抗体（anti-PL-7）组间比较P<0.01；